| BCRJ Code | 0390 |
| Cell Line | HeLa/GFP |
| Species | Homo sapiens |
| Vulgar Name | Human |
| Tissue | Cervix |
| Cell Type | Epithelial |
| Morphology | Epithelial |
| Disease | Adenocarcinoma |
| Growth Properties | Adherent |
| Biosafety | 2 |
| Addtional Info | HeLa cells the most widely used cancer cell lines in the world. These cells were taken from a lady called Henrietta Lacks from her cancerous cervical tumor in 1951 which today is known as the HeLa cells. These were the very first cell lines to survive outside the human body and grow. Both GFP and blasticidin-resistant genes are introduced into parental HeLa cells using lentivirus. |
| Culture Medium | Dulbecco's Modified Eagle's Medium (DMEM) modified to contain 2 mM L-glutamine, 4500 mg/L glucose, 0,1mM MEM Non-Essential Amino Acids (NEAA), 10% of fetal bovine serum (FBS), 10µg/mL Blasticidin. |
| Subculturing Medium Renewal | 2 to 3 times per week |
| Subculturing Subcultivation Ratio | 1:2 to 1:6 |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C |
| Cryopreservation | 95% FBS + 5% DMSO (Dimethyl sulfoxide) |
| Thawing Frozen Cells | SAFETY PRECAUTION:
It is strongly recommended to always wear protective gloves, clothing, and a full-face mask when handling frozen vials. Some vials may leak when submerged in liquid nitrogen, allowing nitrogen to slowly enter the vial. Upon thawing, the conversion of liquid nitrogen back to its gas phase may cause the vial to explode or eject its cap with significant force, creating flying debris.
NOTE: It is important to avoid excessive alkalinity of the medium during cell recovery. To minimize this risk, it is recommended to place the culture vessel containing the growth medium in the incubator for at least 15 minutes before adding the vial contents. This allows the medium to stabilize at its normal pH (7.0 to 7.6). |
| References | 1. Chen, X. et al. (2016). Patterned poly (dopamine) films for enhanced cell adhesion. Bioconj. Chem. doi:10.1021/acs.bioconjchem.6b00544. 2. Castleberry, S. A. et al. (2016). Nanolayered siRNA delivery platforms for local silencing of CTGF reduce cutaneous scar contraction in third-degree burns. Biomaterials. doi:10.1016/j.biomaterials.2016.04.007. 3. Alidori, S. et al. (2016). Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Sci Transl Med. doi:10.1126/scitranslmed.aac9647. 4. Shopsowitz, K. E. et al. (2015). Periodic-shRNA molecules are capable of gene silencing, cytotoxicity and innate immune activation in cancer cells. Nucleic Acids Res. doi:10.1093/nar/gkv1488. 5. Castleberry, S. A. et al. (2015). Self-assembled wound dressings silence MMP-9 and improve diabetic wound healing in vivo. Adv Mater. doi:10.1002/adma.201503565. 6. Dosta, P. et al. (2015). Surface charge tunability as a powerful strategy to control electrostatic interaction for high efficiency silencing, using tailored oligopeptide-modified Poly (beta-amino ester) s (PBAEs). Acta Biomater. doi: 10.1016/j.actbio.2015.03.029. 7. Topete, A. et al. (2014). NIR-light active hybrid nanoparticles for combined imaging and bimodal therapy of cancerous cells. J Mater Chem. 2:6967-6977. 8. Weerakkody, D. et al. (2013). Family of pH (low) Insertion Peptides for Tumor Targeting. PNAS. 110:5834-5839 |
| Depositors | Marcelo Bispo de Jesus - UNICAMP |
| Cellosaurus | CVCL_JY89 |
